US › Healthcare

SAB Biotherapeutics Inc (SABS)

US · Healthcare · Biotechnology

$2.53-2.32%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-22.5M

EPS

$-0.28

EPS estimate

$-0.29

EPS came in at -0.28 against a street estimate of -0.29 — a beat of 3.4%.

Key statistics

Market cap

$243.8M

Forward P/E

0.0

P/B

1.48

Book value

$2.57

EPS (TTM)

$-1.29

52-week high

$5.15

52-week low

$2.10

50-day MA

$3.49

200-day MA

$3.74

Beta

0.58

Analyst view

Analysts rate SAB Biotherapeutics Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $11.64.

Shareholding

Insiders

0.71%

Institutions

75.39%

Largest institutional holders

Fund	Stake
Caligan Partners LP	8.76%
Vivo Capital, LLC	8.02%
Perceptive Advisors LLC	7.28%
Adage Capital Partners Gp LLC	7.04%
RA Capital Management, LLC	4.84%
Balyasny Asset Management LLC	4.13%
BlackRock Inc	3.37%
Vanguard Capital Management, LLC	3.27%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for SAB Biotherapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.